News Perspective Therapeutics, Inc.

Stocks

CATX

US46489V3024

Biotechnology & Medical Research

Market Closed - NYSE 04:00:00 2026-10-23 pm EDT			5-day change	1st Jan Change
1.610 ^USD	-28.76%		-31.20%	-41.45%

Oct. 23	Perspective Therapeutics, Inc. Announces New Interim Results From Ongoing Phase 1/2a Clinical Trial Of [212Pb]VMT-a-NET In Advanced SSTR2-Expressing NETs	CI
Oct. 23	Perspective Reports 'Encouraging' Bamzireotide Profile in Tumor Trial	MT

All News

Mentions Relevance

Oct. 23	Perspective Therapeutics, Inc. Announces New Interim Results From Ongoing Phase 1/2a Clinical Trial Of [212Pb]VMT-a-NET In Advanced SSTR2-Expressing NETs	CI
Oct. 23	Perspective Reports 'Encouraging' Bamzireotide Profile in Tumor Trial	MT
Oct. 08	Perspective Therapeutics, Inc. Receives Fast Track Designation for PSV359 for Treatment of Adult Patients with Locally Advanced Unresectable And/Or Metastatic FAP-Positive Solitary Fibrous Tumors	CI
Oct. 08	Perspective Therapeutics Announces Acceptance of [212Pb]VMT-a-NET Data for Presentation at the NANETS 2026 Multidisciplinary NET Medical Symposium	AQ
Oct. 08	Perspective's Cancer Therapy Candidate Receives FDA Fast Track Designation; Shares Rise Pre-Bell	MT
Oct. 08	Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors	AQ
Oct. 07	Perspective Therapeutics Announces Acceptance of [212Pb]VMT-α-NET Data for Presentation at the NANETS 2026 Multidisciplinary NET Medical Symposium	AQ
Oct. 02	Perspective Therapeutics Announces Acceptance of [212Pb]VMT01 Data for Presentation at SITC 2026	AQ
Sep. 20	Perspective Therapeutics, Inc.(NYSEAM:CATX) dropped from S&P Biotechnology Select Industry Index	CI
Sep. 18	William Blair Initiates Perspective Therapeutics With Outperform Rating	MT
Sep. 14	Perspective Therapeutics, Inc. and Merck Announce Clinical Collaboration and Supply Agreement to Evaluate [212Pb]PSV359 in Combination with Keytruda (Pembrolizumab) in FAP-a Positive Solid Tumors	CI
Sep. 14	Perspective Therapeutics Enters Cancer Clinical Trial Collaboration With Merck; Shares Up Pre-Bell	MT
Sep. 14	Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors	AQ
Sep. 11	Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the 38th EORTC-NCI-AACR Symposium 2026	AQ
Aug. 19	BMO Capital Initiates Perspective Therapeutics at Outperform	MT
Aug. 14	BofA Securities Adjusts Perspective Therapeutics Price Target to $5 From $6	MT
Aug. 11	Perspective Therapeutics's NET Program Data May Allow Phase 3 Trial Start, Value Inflection, RBC Says	MT
Aug. 10	Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2026 Results	AQ
Aug. 10	Perspective Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
Jul. 31	Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2026 Financial Results	AQ
Jul. 28	Perspective Therapeutics' Neuroendocrine Tumor Therapy Receives EU Orphan Drug Designation	MT
Jul. 28	Perspective Therapeutics Receives European Orphan Medicinal Product Designation for [212Pb]VMT-α-NET in GEP-NETs	AQ
Jul. 17	Perspective Therapeutics Data On 212Pb VMT-a-NET Accepted For Oral Presentation At ESMO Congress 2026	CI
Jul. 17	Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Oral Presentation at the ESMO Congress 2026	AQ
Jul. 08	Perspective Therapeutics, Inc. Announces Executive Changes	CI